definiens: means Seller ’s Know -How, other than Transferred Know -How that has specific application to the ownership, operation or conduct of the CF Enterprise, to Develop, Manufacture or Commercialize deuterium -substituted therapeutic agents, i ncluding Know -How to ( i ) assess compounds as suitable targets for deuterium substitution ; ( ii ) synthesize a wide range of chemical compounds that incorporate deuterium selectively at specific positions and accurately analyze deuterium content at those posi tions ; ( iii ) optimize assays to evaluate the metabolic stability and metabolite profile of deuterated compounds ; ( iv ) identify deuterated compounds that possess improved in vitro or in vivo metabolic or pharmacokinetic properties relative to the correspond ing non -deuterated compound ; ( v ) develop and apply bioanalytical methods to identify and measure metabolites formed by the in vitro and in vivo metabolism of deuterated compounds ; ( vi ) understand how the effects of selective deuterium substitution may tran slate from in vitro to in vivo systems and from non -human models to humans, and how deuterium substitution affects individual and population -based ADME parameters ; ( vii ) manufacture, analyze, and formulate deuterated compounds, including development of ana lytical methods for determining level of deuterium incorporation ; and ( viii ) sourcing deuterium reagents, starting materials, and intermediates, and developing and utilizing a supply chain of multiple vendors